Raremark has implemented a new executive team to drive the commercial vision and future growth of the company.
Former Chief Commercial Officer, Jeremy Edwards, has been appointed CEO of Raremark and former Head of Product, Alex Garner, has become COO, while Chairman Neil Rotherham will continue to play an active role in driving the company forward.
Edwards has more than 25 years of experience in the biopharmaceutical and health sciences industry, where he has been instrumental in introducing small, European-based eClinical organizations to the US market, creating new verticals, growing operations, and increasing revenue. At Raremark, Edwards has played an integral role in the company’s rapid growth and development over the last 12 months.
Garner, who has been leading a team to develop novel design and technology concepts that have created the Xperiome platform and Raremark experience.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
Raremark has appointed Caroline O’Connor to join the leadership team as SVP, Business Development. O’Connor brings her wealth of experience in commercial roles in life science technology and services companies. Over the last 9 years her focus has been on eClinical technology, combined with establishing value and driving revenue growth from RWE and Digital Patient Support Programs in the post-approval setting.
“Raremark has created something unique in that they’re helping pharma connect with the most crucial part of the orphan drug development process – the patient,” Dr. Christoph Ruedig, Partner at AlbionVC, said. “The novel patient engagement engine that powers Raremark’s technology will help tackle some of the biggest challenges in the rare disease space, particularly around poor trial design and patient retainment in studies. We are very excited about the progress Raremark will make in disrupting and transforming the way rare disease drugs are being developed.”
“The positive trends and growth in sales over the past six months, led by Jeremy, Alex and the rest of Raremark’s talented team, has given our investors’ confidence and faith in the business and the leadership team to keep the momentum going to allow further expansion of Raremark,” Neil Rotherham, Chairman of Raremark said. “We also recently launched our new patient data platform Xperiome which both Jeremy and Alex were instrumental in helping build and launch. I’m very excited about the progress we’re making and will continue to make with Jeremy and Alex at the helm.”